Cleveland, OH – July 24, 2026 – Checkpoint Surgical, Inc., a leader in intraoperative nerve care and regeneration, announced today that Health Canada has approved the Regen10® Nerve Regeneration System, making the company’s innovative brief electrical stimulation therapeutic device commercially available to surgeons in Canada. The approval marks the first commercial availability of Regen10 and represents an important milestone in Checkpoint Surgical’s mission to advance peripheral nerve care through innovative regenerative technologies.
The Regen10 System is intended to provide electrical stimulation to peripheral nerves to promote regeneration following a severe nerve injury. Developed specifically for peripheral nerve surgery, the system is intended to provide surgeons with a simple, efficient method for delivering a controlled 10-minute dose of electrical stimulation intraoperatively as an adjunct to nerve repair. The commercial launch reflects Checkpoint Surgical’s continued commitment to advancing technologies that help surgeons protect, assess, and regenerate peripheral nerves.
“Receiving Health Canada approval for Regen10 is a significant milestone for Checkpoint Surgical and an exciting step forward for peripheral nerve care,” said Derek Lewis, President and Chief Executive Officer of Checkpoint Surgical. “Canada will be the first market where surgeons have commercial access to Regen10, reflecting our commitment to bringing innovative technologies to clinicians treating peripheral nerve injuries. We look forward to partnering with Canadian surgeons as they incorporate Regen10 into their surgical practice.”
The commercial introduction of Regen10 is supported by decades of scientific research investigating the role of brief electrical stimulation in peripheral nerve regeneration. Through continued clinical research and surgeon collaboration, Checkpoint Surgical remains committed to advancing evidence-based solutions that improve patient care.
Peripheral nerve injuries can significantly impact a patient’s ability to regain sensation and motor function following trauma, tumor resection, or reconstructive procedures. Regen10 provides surgeons with a dedicated platform designed specifically to deliver brief electrical stimulation during nerve repair, complementing existing surgical techniques while supporting the evolving science of peripheral nerve regeneration.
For more information about Regen10 and Checkpoint Surgical’s portfolio of nerve care technologies, visit www.checkpointsurgical.com.
Checkpoint Surgical supports more peripheral nerve procedures than any other device company, offering surgeons a comprehensive continuum of care across the range of nerve surgery. The company’s product portfolio includes the CHECKPOINT GUARDIAN® Nerve Stimulator, CHECKPOINT GEMINI® Bipolar Nerve Stimulator, CHECKPOINT ACMShield® Soft Tissue Barrier, CHECKPOINT EDGE® Nerve Cutting Kit, and now the CHECKPOINT Regen10® Nerve Regeneration System — spanning nerve identification, preservation, repair, and regeneration to address the complete spectrum of peripheral nerve care.
Checkpoint Surgical is a privately held medical device company based in Cleveland, Ohio, dedicated to advancing the science and practice of peripheral nerve care through research, education, and innovative product development. In collaboration with surgeons, the company develops technologies that help protect, assess, and regenerate peripheral nerves. Checkpoint Surgical’s industry leading intraoperative nerve stimulation devices have become the standard of care, and its expanding portfolio of surgical solutions is designed to support the entire continuum of intraoperative nerve care. For more information about Checkpoint Surgical, visit www.checkpointsurgical.com.
